Vikingtherapeutics

NASDAQ: VKTX

1 known investors

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and liver diseases, with a lead candidate VK2735, a dual GLP-1/GIP receptor agonist in Phase 3 obesity trials in both oral and injectable formulations. Its pipeline also includes VK2809 for metabolic and liver diseases and next-generation amylin-based obesity therapies.